Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRaG + IP Serplulimab for Malignant Ascites
NCT05501340Phase 2Unknown
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in malignant ascites and solid tumor, sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoints: Dose-limiting toxicity at 6 months, Treatment Related Severe Adverse Effects at 6 months and 1 more. Status: unknown.
02
Drugs
serplulimab
03
Conditions
malignant ascitessolid tumor
Beyond the preview
Go deeper on NCT05501340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501340.